03 heemskerk eramind mobility mtg_trieste italy_fh_27_may10
Upcoming SlideShare
Loading in...5
×
 

03 heemskerk eramind mobility mtg_trieste italy_fh_27_may10

on

  • 968 views

 

Statistics

Views

Total Views
968
Views on SlideShare
962
Embed Views
6

Actions

Likes
0
Downloads
5
Comments
0

1 Embed 6

http://www.slideshare.net 6

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

03 heemskerk eramind mobility mtg_trieste italy_fh_27_may10 03 heemskerk eramind mobility mtg_trieste italy_fh_27_may10 Presentation Transcript

  • Research, Mobility and commercialisation: ERA-MIND meeting on Mobility Key issues in investing in People Trieste, Italy, May 2010 Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09
  • About a presenter… Frank Heemskerk Academic research (15 yr): Biomedical: Neuroscience HOW does it work? Can we apply this to better therapies? Utrecht (NL) Nat’l Inst Health (USA) UPasteur (FR) But no tenure position... many different grants and working with industrial partners ☺ Personal -international- network ! =>Joint decisions to move: dual careers ! Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 2
  • About a presenter… Frank Heemskerk Industry experience (13 yr): Biotech/pharma, Research Management, contracts, IPR, licensing, partnerships with academia, merger, multiple private investments Moving to Belgium and into Industry How can we use joint knowledge to develop better therapies? International Research Management: Biotech/Pharma, past-President EARMA RIMS bvba founder (2002), board member of several small companies Developing global networks (2500) How can we manage consortia? Develop and grow companies? Create socio-economic value together? Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 3
  • Hard Skills: Soft Skills: - scientific/technical knowledge across - Networking ! disciplines - Teamwork - Project management - Presentation skills ! - Time management - Empathy - Budgeting - negotiation skills Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 4
  • Possible barriers for discussion: 1) personal level: Level of contacts: role of networks skill base: can be developed over time Family situation: dual careers, childres, etc 2) collaboration level: Is industry partner open for hosting? Strutcure of cooperation agreement (IPR, financial transfer, retention, long or short term contracts, one-one or network) Responsible partnering Guidelines, workshops, etc 3) national level: legal, financial/ tax and Social security Role of support/ service centres, job portals/ information services PR on role models in media and schools Allow flexibility in assignments (business people in education...?) Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 5
  • Recommendations for discussion: 1) e.g. Medicine vs Biotech, Chemistry - bad image, but we use products everyday =>PR actions, education, media => Visibility and basic understanding 2) multi-diciplinary teamwork, exchange with industry, projects, interactions between schools and industry ! 3) Help those who want to take initiative: Helpdesks, mentoring schemes, portals PR on role models in media and schools Stimulate networks, associations to help overcome barriers Flexible working conditions Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 6
  • Examples from practise Sharing goodpractices: successful interaction experiences between industry and academia Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 7
  • WHY invest in R&D SMEs? Where is the Value in joint R&D projects? Innovate products and processes Feed pipeline with new/ improved products Diversify portfolio Why invest now?: // current economic climate Access to new knowledge, unique infrastructure, valuable materials, information dbases Achieve critical mass (work faster/disseminate wider/ increase visibility) new experts (future staff?) • Often SMEs drive innovation (products, services, new or niche markets) • quite SMEs can be more flexible// react faster • Attract more public funding to lower risk Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 8
  • Main Objectives: what do you want? What do you want to achieve? Innovate products and processes Feed pipeline with new/ improved products Diversify portfolio Enter new markets enhance visibility What do you want to avoid?: Loose competitive advantage (is always temporary !) loose key knowledge Loose key experts old infrastructure Work in isolation (influencing power) … Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 9
  • Project Management and Value chain Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 10
  • “Due to the proliferation of information in the discovery space, the new R&D business model will evolve to virtual networks of coordinated service providers” Genome Information Network Contract Discovery Toxicogenomics DBs Functional Predictive Modeling HTS and Genomics and Rational Design Combi-Chem DBs Population Metabonomics Genomics DBs Novel Biologics DBs Bioinformatics Target Design ID Formulation & Hardware Manufacturing Regula- Lead Infrastructure B2B Reagent Exchange tory Virtual R&D Discovery Hardware/ASP Formulation Network Clinical Privacy and Valid. Security Automated Chemical Clinical Validation Dri-Science Technology Data Management Synthesis Patient Protocol Planning & Recruitment Bioinformatics Chemi- Management informatics Global Diagnostics & Submission Predictive Modeling Monitoring Source: Accenture Analysis, 2001 Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 11
  • Transfer of knowledge: from academia to...: Academic Consulting, contract research Exchange Graduate students Exchange of staff/ faculty Collaborative Research projects Patenting and licensing Spin-off companies (JV, PPP, etc) Service and out-reach Networking (critical mass) Policy recommendations Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 12
  • Transfer of knowledge: - Ownership (who owns what) ? - Background/Foreground ? - Individual/ Institutional inventorship - (sub)contractor vs partner ? - Acces rights vs User Rights vs Commercialization ? - Co-development? - Financial Conditions (upfront, milestones, IP costs, royalty structure) ? - Partners will have varied levels of experience and expertise in Research management/ Knowledge Transfer practices - Gaps between academics, entrepreneurs and investors: impact on collaborations, practices, need for training, professionalism - International differences: financial, cultural and legal frameworks differ Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 13
  • The Innovation Value chain: Risk perception and your Role Research Development Market Validate Prototypes Industrialize Technol-Commercial Cash needs Value Perceived Risk Parallel Product Development & Transfer at right moment Seed, BA,FFF Local VC Int’l VC IPO Funding Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 14
  • rest of Society/ regulatory Government: ethical legal Academia fiscal infrastructure understanding education! cooperation exchange Understanding matching Industry Investors expectations Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 15
  • Knowledge triangle (FP7) •Added value of an international network (new ideas) •Added value of international exploitation (new applications, mobility) •Critical mass (to fight fragmentation in Europe) Knowledge for Growth Research Open Innovation, Mobility Innov in Educ, new ideas skilled people, Services, products skilled people Knowledge, concepts Education Innovation New multidiscipl. challenges Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 16
  • Academia-Industry: Challenges 1. Communication! 2. Differences in management culture 3. Partners will have varied levels of experience and expertise in Research management/ Knowledge Transfer practices 4. Different timelines (days, years) and expectations (%, €) 5. Lack of insight in business development 6. Insufficient capacity (€, investment) 7. Organizational capacity PLUS: beware of International differences: financial, cultural and legal frameworks differ Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 17
  • “Increasingly international R&D is done in a complex network environment: you need research management professionals to enable the different players to act together” Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 18
  • Project example: M Curie Mobility project in chemical catalysis: Match 2 different academic groups in 2 countries + 1 SME Idea 1 => invite 2 Fellows from across Europe to acquire knowledge for one year at both Universities + 1 fellow for research program in SME Idea 2 => in second stage swap places: industrial fellow goes to academia and 2 academic fellows go to SME VALUE: Consortium to do Research + Development in parallel Matching expertise of 2 different academic fields with industrial requirements Unique transfer of knowledge across borders and sectors Center of excellence for a very focused field with valuable industrial applications High level training events in specialist area Possibly company growth (jobs) and leverage for investment (more €) Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 19
  • example Mexico-Europe cooperation: 1 large prenatal Diagnostics project: 20weeks 12w screening 8 Hospitals : SP (2), BE, SLO, GK, CH, MEX Research Institutes: UK (2) No Preventive Prevention Interventions 3 SMEs: SP, BE and MEX 4 years, 6 M€ Problem: 1.8 million neonatal deaths/year, no early detection method; rate in MEX= 10x EU Objectives: develop diagnostic test (proteomics) and tools (biomarkers) to detect high risk for miscarriage validate in clinical studies in Mexico Transfer knwoledge to Mexico for diagnostic business in LA Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 20
  • example Mexico-Europe cooperation: 2 Large Biofuel project: Universities: NL, AT, MEX Research Institutes: MEX (2), SAfr, Moz SMEs: BE, MEX, NL (3) 3 years, 3.6 M€ Problem: Biofuel from food not sustainable, Mexican Jatropha palms can deliver high yield, but need to be optimized Objectives: select best species (from >300) and characterize (genomics, proteomics) Develop cultivation methods and Optimize oil extraction methods and other side products create business case knowledge transfer between Europe, Mexico and Africa Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 21
  • Cluster example: Small M Curie Chair project: Top female specialist USA => Central European country Idea => Chair at University + research program on HIV vaccine (Nanomedicine) VALUE coming out: Develop larger Consortium to do world class R&D Develop a Clinical trials vaccine cluster: building up specific expertise Center of excellence that is unique for Central-East Europe High level training events in specialist areas Now a spin-off company (jobs) + leverage for investment (private €) Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 22
  • Cluster Strategic Product Development Plan: New ideas pipeline Transfer to others Test with patients: safety+efficacy Build prototypes © VTC ImmuneTherapy cluster Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 23
  • Company example: Flemish region of Belgium Create leverage (industry case): Idea for proprietary HIV assay => patent + specific know how + unique proprietary dbase 1. Enables faster drug discovery progam (core) => attract investment 1 for drug development (Tibotec) 2. Enables Spin-off company for diagnostics=> short term revenue stream (Virco) 3. Enables to attract investment 2 for capacity development => result: Real GROWTH • Tibotec (started 1994) - Virco (started 1995) • 1998: 28 people • 2002: 250 people and acquired by Johnson& Johnson (500 M€) • 2009: 650 people and 2 drugs on the market Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 24
  • Understanding HIV Drug resistance is the key to new drugs Platforms Treatment Genomics monitoring UHTS tools Phenotyping Bioinformatics Phenotypic Genotypic Database Database Pharmacogenomics engine Drug Targets New Drugs Drug Discovery & Development Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 25
  • Research Development Innovation Services Suppliers Products Knowledge Shorter time to market Experienced management access to new markets Strategy building Sufficient private funding Sufficient capacity Consortium building and public funding Expert partners Risk control Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 26
  • Thank you for your attention. Further information: Research & Innovation Management Services bvba Dr Frank Heemskerk E= Frank.Heemskerk@telenet.be T= +32 16 474092 www.rimsinternational.eu Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 27
  • Recommendations: 1. Set internal rules (management decisions, IPR, communication, finance, infrastructure, publications, ...) 2. Create an environment open for collaboration 3. Allow a variety of funding streams 4. Think in processes: (R=>D=>solutions=>more R, etc) Research Mgngmt and Knowledge Transfer offices, but also professionalize support staff, students, etc 5. Communicate effectively to different stakeholders! 6. Innovate the Evaluation of staff, projects, outcomes: not just on # publications, but also on patents, quality of partnerships, socio- economic outcomes, risk, retention of key assets, etc Dr Frank Heemskerk, RIMS bvba; Brussels 26 Febr09 28